Title: Construction of a novel signature based on immune-related lncRNA to identify high and
low risk pancreatic adenocarcinoma patients
Version: 1 Date: 25 May 2023
Reviewer's report:
Thank you for the opportunity to review this manuscript. The authors developed the immune-
related lncRNA signature for pancreatic adenocarcinoma using TCGA data. The manuscript is
interesting, however, there are several issues to address.
1) The results should be validated in independent cohorts. Considering the previous article, there
is an independent cohort (GSE21501).
2) The Lasso regression is good to shrink variables in high-dimensional data, however, there
are several variable selection methods (Pak K et al., JMIR, 2020). The authors should compare
the results from other methods and describe the reasons why they used the lasso with proper
citations.
3) The quality of the figures should be improved. I cannot read them clearly.
Without accurate external validations, the evidence level is not high.
Title: Construction of a novel signature based on immune-related lncRNA to identify high and
low risk pancreatic adenocarcinoma patients
Version: 1 Date: 25 May 2023
Reviewer's report:
Thank you for the opportunity to review this manuscript. The authors developed the immune-
related lncRNA signature for pancreatic adenocarcinoma using TCGA data. The manuscript is
interesting, however, there are several issues to address.
1) The results should be validated in independent cohorts. Considering the previous article, there
is an independent cohort (GSE21501).
2) The Lasso regression is good to shrink variables in high-dimensional data, however, there
are several variable selection methods (Pak K et al., JMIR, 2020). The authors should compare
the results from other methods and describe the reasons why they used the lasso with proper
citations.
3) The quality of the figures should be improved. I cannot read them clearly.
Without accurate external validations, the evidence level is not high.
Please review this paper.
user
Title: Construction of a novel signature based on immune-related lncRNA to identify high and
low risk pancreatic adenocarcinoma patients
Version: 1 Date: 25 May 2023
Reviewer's report:
Thank you for the opportunity to review this manuscript. The authors developed the immune-
related lncRNA signature for pancreatic adenocarcinoma using TCGA data. The manuscript is
interesting, however, there are several issues to address.
1) The results should be validated in independent cohorts. Considering the previous article, there
is an independent cohort (GSE21501).
2) The Lasso regression is good to shrink variables in high-dimensional data, however, there
are several variable selection methods (Pak K et al., JMIR, 2020). The authors should compare
the results from other methods and describe the reasons why they used the lasso with proper
citations.
3) The quality of the figures should be improved. I cannot read them clearly.
Without accurate external validations, the evidence level is not high.
assistant